|drug2990||Saline nasal and throat spray Wiki||1.00|
|drug713||Carrageenan nasal and throat spray Wiki||1.00|
There is one clinical trial.
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infects host-cells via ACE2-receptors, which leads to pneumonia (COVID-19) but also can lead to myocarditis (acute myocardial injury) and chronic damage to the cardiovascular system. Therefore, cardiovascular protection may be necessary when treating patients with COVID-19 infection. This may especially be necessary in patients with cardiovascular diseases, risk factors, and co-medication.
Description: mortality of any causeMeasure: All-cause mortality Time: During 1 year follow-up
Description: mortality of any causeMeasure: 30-day mortality Time: Within 30 days after inclusion
Description: Myocardial infarction, stroke, or CV deathMeasure: Major adverse cardiovascular events Time: During 1 year follow-up
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports